D
Recursion Pharmaceuticals, Inc. RXRX
$6.35 $0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

12/31/2024 09/30/2024 06/30/2024 03/31/2024 12/31/2023
Net Income -41.33% -29.12% -44.21% -42.31% -36.99%
Total Depreciation and Amortization 49.55% 54.99% 103.41% 120.58% 107.57%
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 60.25% 56.90% 57.14% 62.04% 68.40%
Change in Net Operating Assets 24.39% -39.74% -45.59% -47.27% -147.90%
Cash from Operations -24.81% -22.97% -38.09% -35.24% -244.55%
Capital Expenditure -14.55% 19.05% 58.06% 64.55% 67.74%
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions 14,927.33% -103.71% -103.71% -- --
Divestitures -- -- -- -- --
Other Investing Activities -2,763.25% -1,537.77% -104.83% -99.94% -100.05%
Cash from Investing 2,642.62% -13.78% -136.34% -125.87% -105.29%
Total Debt Issued -- -- -- -- --
Total Debt Repaid -479.63% -3,092.63% -719.15% -734.78% -751.11%
Issuance of Common Stock 118.99% 82.36% 165.27% -0.91% -8.76%
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- --
Cash from Financing 117.02% 80.98% 164.93% -1.35% -9.21%
Foreign Exchange rate Adjustments -1,911.70% 178.19% -156.25% 90.61% 161.24%
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash 227.85% 157.07% 239.43% -392.95% -159.78%
Weiss Ratings